Amélie Boespflug
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amélie Boespflug has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Luc Thomas
Dermatology Department Hôpital Lyon Sud, Hospices Civils de Lyon Lyon France
12 shared publications - Stéphane Dalle
Department of Dermatology, Lyon-Sud Hospital, Hospices Civils de Lyon, Centre de Recherche en Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France
10 shared publications - Martin McMahon
Huntsman Cancer Institute
4 shared publications - Mona Foth
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
4 shared publications Courtney C. Cavalieri
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
3 shared publications- Jeffrey T. Yap
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
3 shared publications
Latest Publications
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Thérapies ciblées dans le mélanome : mécanismes impliqués dans les effets paradoxaux, les résistances et évaluation de nouvelles combinaisons
La prise en charge du mélanome métastatique a été bouleversée par les thérapies ciblées comme les inhibiteurs de RAF (RAFi) et les inhibiteurs de MEK (MEKi). Les RAFi permettent dans le mélanome BRAF V600 muté d’améliorer la survie mais leur effet est limité en monothérapie par l’hyperactivation paradoxale de la voie des MAPK dans les cellules non BRAF V600 mutée qui est responsable de l’apparition de mélanomes primitifs induits. Dans ce travail nous montrons la différence entre les modifications transcriptomiques induites par les RAFi dans des lignées cellulaires de mélanome BRAF mutées par rapport à celles induites dans des lignées non BRAF mutées ce qui a permis d’identifier des gènes potentiellement impliqués dans le développement de mélanomes induits. L’efficacité des RAFi est également limitée dans le temps par la survenue de résistances acquises. Nous montrons qu’une charge allélique mutée (CAM) de BRAF V600 élevée est potentiellement associée à une bonne réponse au traitement par RAFi et que la plasticité cellulaire induite par ZEB1 est associée à la résistance aux RAFi. Il n’existe pour le moment pas de thérapie ciblée approuvée dans le mélanome métastatique NRAS muté. Les MEKi sont limités par des résistances qui ne leur ont pas permis d’améliorer significativement la survie des patients. Nous montrons qu’une amplification de NRAS et la mutation MEK P124L sont responsables de résistance aux MEKi dans le mélanome NRAS muté. Nous avons testé le tramétinib (MEKi) en association avec d’autres thérapies ciblées dans des PDX de mélanome NRAS muté afin de mettre en évidence des combinaisons qui améliorent l’efficacité anti tumorale des MEKi dans cette indication
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Thérapies ciblées dans le mélanome : mécanismes impliqués dans les effets paradoxaux, les résistances et évaluation de nouvelles combinaisons
La prise en charge du mélanome métastatique a été bouleversée par les thérapies ciblées comme les inhibiteurs de RAF (RAFi) et les inhibiteurs de MEK (MEKi). Les RAFi permettent dans le mélanome BRAF V600 muté d’améliorer la survie mais leur effet est limité en monothérapie par l’hyperactivation paradoxale de la voie des MAPK dans les cellules non BRAF V600 mutée qui est responsable de l’apparition de mélanomes primitifs induits. Dans ce travail nous montrons la différence entre les modifications transcriptomiques induites par les RAFi dans des lignées cellulaires de mélanome BRAF mutées par rapport à celles induites dans des lignées non BRAF mutées ce qui a permis d’identifier des gènes potentiellement impliqués dans le développement de mélanomes induits. L’efficacité des RAFi est également limitée dans le temps par la survenue de résistances acquises. Nous montrons qu’une charge allélique mutée (CAM) de BRAF V600 élevée est potentiellement associée à une bonne réponse au traitement par RAFi et que la plasticité cellulaire induite par ZEB1 est associée à la résistance aux RAFi. Il n’existe pour le moment pas de thérapie ciblée approuvée dans le mélanome métastatique NRAS muté. Les MEKi sont limités par des résistances qui ne leur ont pas permis d’améliorer significativement la survie des patients. Nous montrons qu’une amplification de NRAS et la mutation MEK P124L sont responsables de résistance aux MEKi dans le mélanome NRAS muté. Nous avons testé le tramétinib (MEKi) en association avec d’autres thérapies ciblées dans des PDX de mélanome NRAS muté afin de mettre en évidence des combinaisons qui améliorent l’efficacité anti tumorale des MEKi dans cette indication
- Open Access
- 1 October 2020
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (19_Supplem) , IA25
Abstract IA25: Targeting MEK1/2 inhibitor resistance in RAS-mutated cancers
Although the RAF>MEK>ERK MAP kinase pathway is key to the development of many RAS-mutated cancers, efforts to target this pathway with pharmacologic inhibitors have failed to deliver clinical benefit to patients. Here we show that inhibition of RAS>RAF>MEK>ERK signaling in RAS-mutated cancer cell lines elicits autophagy, a process of cellular recycling that protects cancer cells from the potentially cytotoxic effects of RAF>MEK>ERK pathway inhibition. Furthermore, combined inhibition of MEK1/2 plus autophagy displays synergistic antiproliferative effects against cell lines in vitro and promotes regression of xenografted patient-derived tumors in mice. Finally, treatment of a cancer patient with the combination of trametinib plus hydroxychloroquine resulted in a partial, but nonetheless striking, disease response. These data suggest that this combination therapy may represent a novel strategy to target RAS-driven malignancies such as melanoma, lung, and pancreatic cancer. Citation Format: Conan Kinsey, Soledad Camolotto, Amelie Boespflug, Katrin Gullien, Amanda Truong, Mona Foth, Jill Shea, Michael Seipp, Jeffrey Yap, Lance Burrell, David Lum, Jonathan Whisenant, Courtney Cavalier, Kaitren Rehbein, Stephanie Cutler, Kajsa Afotler, Alana Welm, Bryan Welm, Courtney Scaife, Eric Snyder, Martin McMahon. Targeting MEK1/2 inhibitor resistance in RAS-mutated cancers [abstract]. In: Proceedings of the AACR Special Conference on Melanoma: From Biology to Target; 2019 Jan 15-18; Houston, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(19 Suppl):Abstract nr IA25.
- 1 October 2020
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (19_Supplem) , IA25
Open AccessAbstract IA25: Targeting MEK1/2 inhibitor resistance in RAS-mutated cancers
Although the RAF>MEK>ERK MAP kinase pathway is key to the development of many RAS-mutated cancers, efforts to target this pathway with pharmacologic inhibitors have failed to deliver clinical benefit to patients. Here we show that inhibition of RAS>RAF>MEK>ERK signaling in RAS-mutated cancer cell lines elicits autophagy, a process of cellular recycling that protects cancer cells from the potentially cytotoxic effects of RAF>MEK>ERK pathway inhibition. Furthermore, combined inhibition of MEK1/2 plus autophagy displays synergistic antiproliferative effects against cell lines in vitro and promotes regression of xenografted patient-derived tumors in mice. Finally, treatment of a cancer patient with the combination of trametinib plus hydroxychloroquine resulted in a partial, but nonetheless striking, disease response. These data suggest that this combination therapy may represent a novel strategy to target RAS-driven malignancies such as melanoma, lung, and pancreatic cancer. Citation Format: Conan Kinsey, Soledad Camolotto, Amelie Boespflug, Katrin Gullien, Amanda Truong, Mona Foth, Jill Shea, Michael Seipp, Jeffrey Yap, Lance Burrell, David Lum, Jonathan Whisenant, Courtney Cavalier, Kaitren Rehbein, Stephanie Cutler, Kajsa Afotler, Alana Welm, Bryan Welm, Courtney Scaife, Eric Snyder, Martin McMahon. Targeting MEK1/2 inhibitor resistance in RAS-mutated cancers [abstract]. In: Proceedings of the AACR Special Conference on Melanoma: From Biology to Target; 2019 Jan 15-18; Houston, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(19 Suppl):Abstract nr IA25.
- 1 May 2020
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (5_Suppleme) , A45
Abstract A45: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Pancreatic ductal adenocarcinoma was responsible for ~43,000 deaths in the USA in 2017 and is the epitome of a recalcitrant cancer driven by a pharmacologically intractable oncoprotein, KRAS. Although the clinical picture remains grim, the mechanisms by which key alterations in tumor suppressors and proto-oncogenes contribute to PDA have been dissected. Downstream of KRAS, the RAF→MEK→ERK signaling pathway plays a central role in pancreatic carcinogenesis. However, to date, pharmacologic inhibition of this pathway has provided no clinical benefit to PDA patients. Here we show that inhibition of KRAS→RAF→MEK→ERK signaling in PDA cell lines elicits autophagy, a process of cellular recycling that protects pancreatic cancer cells from the potentially cytotoxic effects of KRAS pathway inhibition. Furthermore, combined inhibition of MEK1/2 plus autophagy displays synergistic antiproliferative effects against PDA cell lines in vitro, and promotes regression of xenografted patient-derived PDA tumors in mice. Finally, treatment of a KRAS-mutated PDA patient on a compassionate basis with the combination of trametinib plus hydroxychloroquine resulted in a partial but nonetheless striking disease response. These data suggest that this combination therapy may represent a new strategy to target RAS-driven cancers such as PDA. Citation Format: Conan G. Kinsey, Soledad A. Camolotto, Amelie M. Boespflug, Katrin P. Gullien, Mona Foth, Jill E. Shea, Michael T. Seipp, Jeffrey T. Yap, Lance D. Burrell, David H. Lum, Jonathan R. Whisenant, Weldon Gilcrease, Courtney C. Cavalieri, Kaitrin M. Rehbein, Stephanie L. Cutler, Kajsa E. Affolter, Alana L. Welm, Bryan E. Welm, Courtney L. Scaife, Eric L. Snyder, Martin McMahon. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers [abstract]. In: Proceedings of the AACR Special Conference on Targeting RAS-Driven Cancers; 2018 Dec 9-12; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(5_Suppl):Abstract nr A45.
- 1 May 2020
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (5_Suppleme) , A45
Abstract A45: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Pancreatic ductal adenocarcinoma was responsible for ~43,000 deaths in the USA in 2017 and is the epitome of a recalcitrant cancer driven by a pharmacologically intractable oncoprotein, KRAS. Although the clinical picture remains grim, the mechanisms by which key alterations in tumor suppressors and proto-oncogenes contribute to PDA have been dissected. Downstream of KRAS, the RAF→MEK→ERK signaling pathway plays a central role in pancreatic carcinogenesis. However, to date, pharmacologic inhibition of this pathway has provided no clinical benefit to PDA patients. Here we show that inhibition of KRAS→RAF→MEK→ERK signaling in PDA cell lines elicits autophagy, a process of cellular recycling that protects pancreatic cancer cells from the potentially cytotoxic effects of KRAS pathway inhibition. Furthermore, combined inhibition of MEK1/2 plus autophagy displays synergistic antiproliferative effects against PDA cell lines in vitro, and promotes regression of xenografted patient-derived PDA tumors in mice. Finally, treatment of a KRAS-mutated PDA patient on a compassionate basis with the combination of trametinib plus hydroxychloroquine resulted in a partial but nonetheless striking disease response. These data suggest that this combination therapy may represent a new strategy to target RAS-driven cancers such as PDA. Citation Format: Conan G. Kinsey, Soledad A. Camolotto, Amelie M. Boespflug, Katrin P. Gullien, Mona Foth, Jill E. Shea, Michael T. Seipp, Jeffrey T. Yap, Lance D. Burrell, David H. Lum, Jonathan R. Whisenant, Weldon Gilcrease, Courtney C. Cavalieri, Kaitrin M. Rehbein, Stephanie L. Cutler, Kajsa E. Affolter, Alana L. Welm, Bryan E. Welm, Courtney L. Scaife, Eric L. Snyder, Martin McMahon. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers [abstract]. In: Proceedings of the AACR Special Conference on Targeting RAS-Driven Cancers; 2018 Dec 9-12; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(5_Suppl):Abstract nr A45.
- 23 August 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (2) , E57-E59
Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue‐white veil
- 23 August 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (2) , E57-E59
Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue‐white veil
- 27 March 2019
- Published by Springer Nature in Nature Medicine
- Vol. 25 (5) , 861
Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
In the version of this article initially published, the label over the bottom schematic in Fig. 1a was “pH > 5.0”; it should have been “pH < 5.0”. Further, the original article misspelt the surname of Katrin P. Guillen as “Gullien”. These errors have been corrected in the print, PDF and HTML versions of the article.
- 27 March 2019
- Published by Springer Nature in Nature Medicine
- Vol. 25 (5) , 861
Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
In the version of this article initially published, the label over the bottom schematic in Fig. 1a was “pH > 5.0”; it should have been “pH < 5.0”. Further, the original article misspelt the surname of Katrin P. Guillen as “Gullien”. These errors have been corrected in the print, PDF and HTML versions of the article.
- Top Cited Papers
- 4 March 2019
- Published by Springer Nature in Nature Medicine
- Vol. 25 (4) , 620-627
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Pancreatic ductal adenocarcinoma (PDA) was responsible for ~ 44,000 deaths in the United States in 2018 and is the epitome of a recalcitrant cancer driven by a pharmacologically intractable oncoprotein, KRAS1,2,3,4. Downstream of KRAS, the RAF→MEK→ERK signaling pathway plays a central role in pancreatic carcinogenesis5. However, paradoxically, inhibition of this pathway has provided no clinical benefit to patients with PDA6. Here we show that inhibition of KRAS→RAF→MEK→ERK signaling elicits autophagy, a process of cellular recycling that protects PDA cells from the cytotoxic effects of KRAS pathway inhibition. Mechanistically, inhibition of MEK1/2 leads to activation of the LKB1→AMPK→ULK1 signaling axis, a key regulator of autophagy. Furthermore, combined inhibition of MEK1/2 plus autophagy displays synergistic anti-proliferative effects against PDA cell lines in vitro and promotes regression of xenografted patient-derived PDA tumors in mice. The observed effect of combination trametinib plus chloroquine was not restricted to PDA as other tumors, including patient-derived xenografts (PDX) of NRAS-mutated melanoma and BRAF-mutated colorectal cancer displayed similar responses. Finally, treatment of a patient with PDA with the combination of trametinib plus hydroxychloroquine resulted in a partial, but nonetheless striking disease response. These data suggest that this combination therapy may represent a novel strategy to target RAS-driven cancers.
- 4 March 2019
- Published by Springer Nature in Nature Medicine
- Vol. 25 (4) , 620-627
Top Cited PapersProtective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Pancreatic ductal adenocarcinoma (PDA) was responsible for ~ 44,000 deaths in the United States in 2018 and is the epitome of a recalcitrant cancer driven by a pharmacologically intractable oncoprotein, KRAS1,2,3,4. Downstream of KRAS, the RAF→MEK→ERK signaling pathway plays a central role in pancreatic carcinogenesis5. However, paradoxically, inhibition of this pathway has provided no clinical benefit to patients with PDA6. Here we show that inhibition of KRAS→RAF→MEK→ERK signaling elicits autophagy, a process of cellular recycling that protects PDA cells from the cytotoxic effects of KRAS pathway inhibition. Mechanistically, inhibition of MEK1/2 leads to activation of the LKB1→AMPK→ULK1 signaling axis, a key regulator of autophagy. Furthermore, combined inhibition of MEK1/2 plus autophagy displays synergistic anti-proliferative effects against PDA cell lines in vitro and promotes regression of xenografted patient-derived PDA tumors in mice. The observed effect of combination trametinib plus chloroquine was not restricted to PDA as other tumors, including patient-derived xenografts (PDX) of NRAS-mutated melanoma and BRAF-mutated colorectal cancer displayed similar responses. Finally, treatment of a patient with PDA with the combination of trametinib plus hydroxychloroquine resulted in a partial, but nonetheless striking disease response. These data suggest that this combination therapy may represent a novel strategy to target RAS-driven cancers.
- 1 March 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 80 (3) , e63-e64
Reply to “Comment on ‘Association of subungual melanoma and subungual squamous cell carcinoma: A case series’”
- 1 March 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 80 (3) , e63-e64
Reply to “Comment on ‘Association of subungual melanoma and subungual squamous cell carcinoma: A case series’”
- 16 October 2018
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 42 (2) , 304-307
Percutaneous Cryotherapy for Treatment of Chondroblastoma: Early Experience
Surgical curettage is currently the standard of care for the chondroblastoma, but in peri-articular tumors it is limited by its morbidity. In this preliminary report, we evaluate the feasibility of percutaneous cryotherapy as an alternative ablative treatment for chondroblastoma. Three patients with a chondroblastoma treated by CT scan-guided cryotherapy are presented in this article. Pain permanently disappeared 2 days after the procedure. No local tumor recurrence or cartilage damage was observed by MRI performed 1 year after the intervention. This preliminary case report suggests that percutaneous cryotherapy may be a possible alternative to the current standard of care in chondroblastoma. Further studies are needed to evaluate if this technique offers similar anti-tumoral efficacy while providing better pain relief and less morbidity than curettage.
- 16 October 2018
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 42 (2) , 304-307
Percutaneous Cryotherapy for Treatment of Chondroblastoma: Early Experience
Surgical curettage is currently the standard of care for the chondroblastoma, but in peri-articular tumors it is limited by its morbidity. In this preliminary report, we evaluate the feasibility of percutaneous cryotherapy as an alternative ablative treatment for chondroblastoma. Three patients with a chondroblastoma treated by CT scan-guided cryotherapy are presented in this article. Pain permanently disappeared 2 days after the procedure. No local tumor recurrence or cartilage damage was observed by MRI performed 1 year after the intervention. This preliminary case report suggests that percutaneous cryotherapy may be a possible alternative to the current standard of care in chondroblastoma. Further studies are needed to evaluate if this technique offers similar anti-tumoral efficacy while providing better pain relief and less morbidity than curettage.
- 1 April 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 78 (4) , 760-768
Association of subungual melanoma and subungual squamous cell carcinoma: A case series
- 1 April 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 78 (4) , 760-768
Association of subungual melanoma and subungual squamous cell carcinoma: A case series
- 24 March 2018
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 32 (8) , 1368-1372
RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH
Background Patients treated with vemurafenib for metastatic melanoma often develop skin lesions similar to those observed after exposure to dioxin‐like compounds. We previously called these lesions MADISH (metabolizing acquired dioxin‐induced skin hamartoma) when analysing a case of acute dioxin poisoning. Objective We performed a clinical trial aimed at comparing the skin lesions observed under vemurafenib treatment with MADISH in order to bring to light a possible crosstalk between vemurafenib and dioxin pathways. Methods In this case series study, we explored the histological aspect of skin lesions in 10 cases treated with vemurafenib for malignant melanoma. We also analysed the ability of vemurafenib and tyrosine kinase inhibitors to induce dioxin–AhR pathway. Results All patients had skin lesions diagnosed as ‘non‐inflammatory acneiform eruption’ by dermatologists. These were predominantly facial with notable retroauricular involvement and clinically compatible with chloracne/MADISH when assessed by dioxin expert. Histological analysis showed mostly comedone‐like lesions and dermal cysts containing epithelial wall with basal or lateral epithelial projections and lamellar keratinization and alterations of remaining sebaceous glands. The expression of CYP1A1, a gene highly induced following dioxin exposure, was not observed in these lesions. Vemurafenib and the tyrosine kinase inhibitors erlotinib and gefitinib did not induce CYP1A1 activity. Discussion Although the skin lesions under vemurafenib treatment were morphologically similar to MADISH, the absence of CYP1A1 expression in dermal cysts of patients and the absence of CYP1A1 activation by vemurafenib led us consider that these skin lesions were different from true MADISH and not mediated by a crosstalk of AhR signalling, but rather to a hyperactivation of PI3K‐Akt pathway as a consequence of vemurafenib treatment. A strong expression of CYP1A1 in the epithelial wall of dermal cysts must be required, parallel to the morphology of the lesions, to make the diagnosis of MADISH, the hallmark of an exposure to dioxin‐like/chloracnegen compounds.
- 24 March 2018
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 32 (8) , 1368-1372
RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH
Background Patients treated with vemurafenib for metastatic melanoma often develop skin lesions similar to those observed after exposure to dioxin‐like compounds. We previously called these lesions MADISH (metabolizing acquired dioxin‐induced skin hamartoma) when analysing a case of acute dioxin poisoning. Objective We performed a clinical trial aimed at comparing the skin lesions observed under vemurafenib treatment with MADISH in order to bring to light a possible crosstalk between vemurafenib and dioxin pathways. Methods In this case series study, we explored the histological aspect of skin lesions in 10 cases treated with vemurafenib for malignant melanoma. We also analysed the ability of vemurafenib and tyrosine kinase inhibitors to induce dioxin–AhR pathway. Results All patients had skin lesions diagnosed as ‘non‐inflammatory acneiform eruption’ by dermatologists. These were predominantly facial with notable retroauricular involvement and clinically compatible with chloracne/MADISH when assessed by dioxin expert. Histological analysis showed mostly comedone‐like lesions and dermal cysts containing epithelial wall with basal or lateral epithelial projections and lamellar keratinization and alterations of remaining sebaceous glands. The expression of CYP1A1, a gene highly induced following dioxin exposure, was not observed in these lesions. Vemurafenib and the tyrosine kinase inhibitors erlotinib and gefitinib did not induce CYP1A1 activity. Discussion Although the skin lesions under vemurafenib treatment were morphologically similar to MADISH, the absence of CYP1A1 expression in dermal cysts of patients and the absence of CYP1A1 activation by vemurafenib led us consider that these skin lesions were different from true MADISH and not mediated by a crosstalk of AhR signalling, but rather to a hyperactivation of PI3K‐Akt pathway as a consequence of vemurafenib treatment. A strong expression of CYP1A1 in the epithelial wall of dermal cysts must be required, parallel to the morphology of the lesions, to make the diagnosis of MADISH, the hallmark of an exposure to dioxin‐like/chloracnegen compounds.